E. Ohman J or Asset Management AB Acquires New Holdings in Astrana Health, Inc. (NASDAQ:ASTH)

E. Ohman J or Asset Management AB acquired a new stake in Astrana Health, Inc. (NASDAQ:ASTH) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 33,000 shares of the company’s stock, valued at approximately $1,040,000.

Several other institutional investors and hedge funds have also modified their holdings of ASTH. GAMMA Investing LLC acquired a new position in shares of Astrana Health in the 3rd quarter valued at approximately $34,000. Nisa Investment Advisors LLC acquired a new position in shares of Astrana Health in the 3rd quarter valued at approximately $35,000. KBC Group NV acquired a new position in shares of Astrana Health in the 3rd quarter valued at approximately $70,000. Quarry LP acquired a new position in shares of Astrana Health in the 3rd quarter valued at approximately $77,000. Finally, Quest Partners LLC acquired a new position in shares of Astrana Health in the 3rd quarter valued at approximately $133,000. 52.77% of the stock is currently owned by institutional investors and hedge funds.

Astrana Health Stock Down 1.2 %

ASTH stock opened at $36.53 on Thursday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. The stock has a market capitalization of $2.05 billion, a price-to-earnings ratio of 28.10, a PEG ratio of 1.42 and a beta of 1.20. The business’s fifty day moving average price is $35.91 and its two-hundred day moving average price is $46.06. Astrana Health, Inc. has a fifty-two week low of $29.08 and a fifty-two week high of $63.20.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. The firm had revenue of $478.71 million for the quarter, compared to analysts’ expectations of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same quarter last year, the business earned $0.47 EPS. On average, equities analysts anticipate that Astrana Health, Inc. will post 1.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

ASTH has been the subject of a number of recent research reports. TD Cowen initiated coverage on Astrana Health in a research report on Monday, October 14th. They set a “buy” rating and a $66.00 price target for the company. KeyCorp initiated coverage on Astrana Health in a research report on Friday, October 11th. They set a “sector weight” rating for the company. Robert W. Baird upped their price target on Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Truist Financial reduced their price target on Astrana Health from $59.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, January 13th. Finally, Macquarie raised Astrana Health to a “hold” rating in a research report on Monday, December 16th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $63.67.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.